Advertisement

Search Results

Advertisement



Your search for ,OUr matches 10645 pages

Showing 3651 - 3700


Cancer in Older Adults: The History of Geriatric Oncology, 1980–2015

The development of geriatric oncology has been slow but progressive. Thanks to the effort of investigators throughout the world, embattled but undeterred by the objection of a cautious establishment, geriatric oncology has provided a blueprint for the treatment of cancer in the population of...

multiple myeloma

Red Flag Presentations of Immunoglobulin Light Chain Amyloidosis in Patients With Multiple Myeloma

The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that occasionally quizzes readers on issues in hematology. In this installment, the authors highlight the most common type of systemic amyloidosis in the United States: immunoglobulin light chain [or amyloid light...

Emmanuelle Charpentier, PhD, and Jennifer A. Doudna, PhD, Honored With Nobel Prize in Chemistry 2020

On October 7, 2020, The Royal Swedish Academy of Sciences announced that the Nobel Prize in Chemistry 2020 would be awarded to Emmanuelle Charpentier, PhD, and Jennifer A. Doudna, PhD, “for the development of a method for genome editing,” the CRISPR/Cas9 genetic scissors. “There is enormous power...

breast cancer

Breast Cancer Risk After Benign Breast Disease

Benign breast disease is known to increase the chances of subsequent breast cancer. According to Spanish researchers, the way benign breast disease is detected may be an indication of how likely it is to become cancerous. The findings from the team led by Xavier Castells, MD, PhD, Head of the...

issues in oncology
covid-19

Study Finds Black and Hispanic Patients With Cancer Used Telehealth Less Often Than White Patients During the COVID-19 Pandemic

During the peak of the COVID-19 pandemic, fewer Black and Hispanic patients with cancer used telehealth (including phone encounters and video visits) compared to White patients, according to findings from an analysis of data from New York City hospitals. Significant disparities in the use of...

issues in oncology

Survey of Health-Care Providers Finds Knowledge About Unique Needs of LGBTQ Patients With Cancer Is Limited

A 2018 study by Cathcart-Rake et al in the journal Cancer on the rates of acquisition of sexual orientation and gender identity data among community oncology practices found that only 24% of these practices routinely asked patients about their sexual orientation, and only 10% asked about gender...

colorectal cancer
immunotherapy

Study Finds Disparities in Microsatellite Instability/Mismatch Repair Biomarker Testing for Patients With Stage IV Colorectal Cancer

Immune checkpoint inhibitors have improved outcomes for patients with a variety of cancer types, including those with advanced colorectal cancers that test positive for microsatellite instability/mismatch repair deficiency (MSI-high/MMRd). While testing rates for patients with MSI-high/MMRd...

breast cancer

Emerging Alternatives in the Third-Line Setting for Metastatic HER2-Positive Breast Cancer

In the post-trastuzumab era, a number of U.S. Food and Drug Administration (FDA)-approved targeted agents for metastatic HER2-positive breast cancer are available, but there is no preferred option for third-line treatment and beyond. At the 2019 Chemotherapy Foundation Symposium, Shanu Modi, MD,...

breast cancer

Updates From Additional Clinical Trials in HER2-Positive Breast Cancer

Here we present summaries of several additional clinical trials in HER2-positive breast cancer reported over the past year. Jame Abraham, MD, Chair of the Division of Hematology and Oncology at the Taussig Cancer Center, Cleveland Clinic, shared his perspective on several of these trials presented ...

breast cancer

Abemaciclib/Fulvestrant/Trastuzumab for Patients With Previously Treated HR-Positive, HER2-Positive Advanced Breast Cancer

In the phase II monarcHER trial reported in The Lancet Oncology, Sara M. Tolaney, MD, of Dana-Farber Cancer Institute, Boston, and colleagues, found that the combination of abemaciclib, fulvestrant, and trastuzumab prolonged progression-free survival vs trastuzumab plus standard-of-care...

breast cancer
immunotherapy

IMpassion131: No Benefit for Atezolizumab Plus Paclitaxel in Triple-Negative Breast Cancer

Based on some unexpected negative results, oncologists using atezolizumab for metastatic triple-negative breast cancer should pair it with nab-paclitaxel, not paclitaxel. In contrast to the overall survival benefit shown for atezolizumab plus nab-paclitaxel in the previous IMpassion130...

gastrointestinal cancer

Long-Term Outcomes With Neoadjuvant Therapy Followed by Surgery in Rectal Adenocarcinoma: Focus on Pathologic Response

For patients with rectal adenocarcinoma treated with neoadjuvant therapy followed by operative resection, “achieving a pathologic complete response is associated with excellent long-term disease-free and overall survival,” according to the results of a study reported by Naomi M. Sell, MD, MHS, of...

issues in oncology
covid-19

ASCO’s National Cancer Opinion Survey Reveals Concerns Over Delays in Cancer Screenings Due to COVID-19 and Inequities in Health Care

Findings from ASCO’s fourth annual National Cancer Opinion Survey showed the toll the COVID-19 pandemic is taking on patients with cancer and the concerns over delays in scheduling cancer screenings. In addition, a majority of survey respondents acknowledged that racism can impact the care a person ...

prostate cancer

Long-Term Impact of ADT in Favorable vs Unfavorable Intermediate-Risk Prostate Cancer

In an analysis of long-term data from NRG Oncology’s RTOG 9408 trial reported in JAMA Network Open, Zumsteg et al found that patients with favorable vs unfavorable intermediate-risk prostate cancer had improved overall survival, and that androgen-deprivation therapy (ADT) vs no ADT was associated...

neuroendocrine tumors

Novel Small-Molecule Inhibitor Surufatinib for Advanced Extrapancreatic Neuroendocrine Tumors

In the Chinese phase III SANET-ep trial reported in The Lancet Oncology, Xu et al found that surufatinib improved progression-free survival vs placebo in patients with advanced extrapancreatic neuroendocrine tumors. Surufatinib is a novel small-molecule inhibitor that targets VEGFR-1, VEGFR-2,...

issues in oncology

Ending Systemic Racism in Oncology Is Everyone’s Responsibility

Five years ago, as Rachel B. Issaka, MD, MAS, was beginning her second year as a gastroenterology fellow and feeling proud of the progress she was making in her training, she was suddenly confronted with an all-too-familiar slight that underrepresented minority providers may often experience. As...

issues in oncology

An MSK Hospitalist Looks at Oncologists’ Attitudes About Inpatient Cancer Care

Each year in the United States, about five million adults with cancer are admitted to hospitals. Given our aging population, this trend will increase, putting added stress on the oncology community, which is already dealing with an impending workforce shortage. Although physician extenders, such...

Sylvester Comprehensive Cancer Center Receives $126 Million Gift

A gift of $126 million to the Sylvester Comprehensive Cancer Center at the University of Miami Leonard M. Miller School of Medicine will accelerate advances in finding cures for cancer and expand innovative treatment options. The donation is the single largest in the University of Miami’s 95-year...

pancreatic cancer

Study Finds Recent-Onset Diabetes With Unintentional Weight Loss Linked to Increased Risk of Pancreatic Cancer

A large cohort study with close to 160,000 men and women reported that “recent-onset diabetes accompanied by weight loss was associated with a substantial increase in risk for pancreatic cancer and may represent a high-risk group in the general population for whom early detection strategies would...

Regional Council for a Stronger Society

In 2019, ASCO launched an Asia-Pacific Regional Council, a group of distinguished oncology leaders from countries in the Asia-Pacific region. The Council’s purpose is to advise ASCO on the needs of members in the region and facilitate and encourage member involvement in ASCO’s global activities....

Conquer Cancer Collaborates With Israel Cancer Research Fund for Career Development Award in Israel

Conquer Cancer®, the ASCO Foundation has joined forces with the Israel Cancer Research Fund (ICRF) to grant a 2020 Career Development Award (CDA) to a physician-scientist in Israel. The CDA supports early-career clinical and translational investigators during their first few years of faculty...

global cancer care

Cancer in My Community: Caring for Children With Cancer in Armenia

Cancer in My Community is a Cancer.Net Blog series that shows the global impact of cancer and how providers work to care for people with cancer in their region. Why I Care for People With Cancer When you tell someone that you are a pediatric oncologist and treat children with cancer, the first...

Leading Cancer Treatment Recommendations From NCCN Available in Several Languages

The National Comprehensive Cancer Network® (NCCN®) has announced the availability of multiple non–English-language versions of the NCCN Clinical Practice Guidelines in Oncology® (NCCN Guidelines®) for numerous high-incidence cancer types. These treatment recommendations can be accessed for free at...

Cancer Center at Brown University Established

The Corporation of Brown University has approved the establishment of the Cancer Center at Brown. The center takes a broad-spectrum approach to research, from working to understand how cancer develops, grows, and metastasizes, to developing new therapeutics for patients in a personalized way that...

lymphoma

Good Outcomes With PET-Directed Therapy for Limited-Stage Diffuse Large B-Cell Lymphoma

As reported in the Journal of Clinical Oncology by Daniel O. Persky, MD, of the University of Arizona Cancer Center, Tucson, and colleagues, the phase II Intergroup National Clinical Trials Network Study S1001 has shown good outcomes with positron-emission tomography (PET)-directed therapy in...

Many Reasons to ‘Geriatricize’ Your Oncology Practice: Research Updates From ASCO20

“Older adults form the majority of patients with cancer.” For more than 3 decades now, almost every article, presentation, or discussion related to cancer and aging started with this statement. As I entered the field of geriatric oncology, I thought that by simply stating this fact, everyone would...

colorectal cancer

I’ve Turned My Pain Into a New Life Purpose

The first half of 2016 was arguably the most exciting of my life. My wife, Jaione, and I had decided to leave the United Kingdom and move with our two children, Andrew, then 14, and Alba, then 10, to Denver, where I was taking on a leadership role in corporate affairs for a brewery company. By the...

Never Say Never

She was elderly, slightly confused, and very, very worried. I was not quite sure why. It was a minor procedure—a routine angiogram, one of a dozen to be performed that morning. The risks were so small that the job of admitting her had been handed to me, then a final-year medical student, with a...

gynecologic cancers

Early Cancer Experience Plants the Seed for a Career in Oncology to Grow for Joyce F. Liu, MD, MPH

As a young girl growing up in central New Jersey, Joyce F. Liu, MD, MPH, a medical oncologist specializing in gynecologic cancers at Dana-Farber Cancer Institute, Boston, dreamed of becoming an astronaut. However, she realized her fear of heights and propensity for motion sickness didn’t jive with...

skin cancer

Sentinel Lymph Node Biopsy and Age-Related Mutations: Therapeutic and Predictive Implications in Melanoma

Findings from a study among patients with melanoma randomly assigned to observation following removal of a positive sentinel lymph node “strongly support the therapeutic effect of the sentinel lymph node biopsy in providing long-term regional nodal disease control in the large majority of...

gastrointestinal cancer

Avapritinib Produces High Response Rate in Advanced PDGFRA D842V–Mutant GIST

As reported inThe Lancet Oncology by Michael C. Heinrich, MD, of the VA Portland Health Care System and the Oregon Health & Science University Knight Cancer Institute, and colleagues, the phase I NAVIGATOR trial showed that the PDGFRA and KIT kinase inhibitor avapritinib produced a high...

breast cancer

Age at Diagnosis May Improve Risk Stratification for Patients With Breast Cancer

Age is not just a number when it comes to prognosis for invasive breast cancer. According to data presented during the 2020 Society of Surgical Oncology (SSO) International Conference on Surgical Cancer Care, age at diagnosis of breast cancer is a highly prognostic clinical variable that warrants...

head and neck cancer

Neoadjuvant Chemotherapy Alone vs Chemoradiation in Esophageal Cancer: No Difference Found in Long-Term Survival

Improved local-regional tumor control may not be enough to justify the increased morbidity of adding neoadjuvant radiation to chemotherapy in esophageal and gastroesophageal junction cancers, according to a pair of studies presented during the 2020 Society of Surgical Oncology (SSO) International...

Expert Point of View: George J. Chang, MD, MS, FACS, FASCRS

George J. Chang, MD, MS, FACS, FASCRS, of the Department of Surgical Oncology at The University of MD Anderson Cancer Center, told The ASCO Post that although adjuvant therapy in stage II disease has been shown to improve outcomes in patients with certain high-risk features, “the benefits are...

gastrointestinal cancer

Is Infiltrating Tumor Border Configuration Linked to Poor Survival in Colon Adenocarcinoma?

Findings from a retrospective cohort study could fuel the debate over the use of adjuvant chemotherapy in stage II colon cancer, according to data presented during the virtual edition of the 2020 Society of Surgical Oncology (SSO) International Conference on Surgical Cancer Care.1 Results of the...

lymphoma

Disparities and Incidence of Late Effects of Treatment for AYA Lymphoma Survivors

The late effects of adolescent and young adults (AYA) with lymphomas are considerable and have not been given much attention, according to Theresa Keegan, MD, of the University of California at Davis. “Lymphoma is one of the most commonly occurring malignancies in AYAs,” she stated. “The 5-year...

The New Face of Medical Visits

“Good morning! I’m Dr. Saksena. It’s a pleasure to meet you.” I wave my introduction as I enter the room. Two women sit beside each other. One of them wears a mask that reads “lipstick optional,” and the other dons a surgical mask. This is a new visit for breast cancer, but I haven’t yet deciphered ...

issues in oncology

Efforts to Broaden Eligibility Criteria for Clinical Trials Seek to Include More Racial and Ethnic Minority Patients

A review of the 2019 Drug Trials Snapshots Report1 from the U.S. Food and Drug Administration (FDA) showed that although female participation in clinical trials grew to 72% from 56% in the FDA’s 2018 Drug Trials Snapshots Report,2 ethnic minority participation in clinical trials actually declined...

lung cancer
immunotherapy

Continuous vs Fixed-Duration Immunotherapy in Previously Treated Patients With Advanced NSCLC

In an exploratory analysis of the phase IIIb/IV CheckMate 153 trial published in the Journal of Clinical Oncology, David M. Waterhouse, MD, MPH, and colleagues found that continuing nivolumab beyond 1 year of treatment vs stopping at 1 year of treatment was associated with better outcomes in...

breast cancer
genomics/genetics

Use of ctDNA to Direct Therapy in Advanced Breast Cancer

In the phase IIa plasmaMATCH platform trial reported in The Lancet Oncology, Nicholas C. Turner, MD, and colleagues found that circulating tumor DNA (ctDNA) provided accurate genotyping that permitted selection of directed therapies in patients with advanced breast cancer. Study Details The...

issues in oncology
legislation
health-care policy
covid-19

AACR Releases 10th Edition of Annual Cancer Progress Report

The American Association for Cancer Research (AACR) has released the 10th edition of its annual Cancer Progress Report. The report highlights how cancer research, largely supported by federal investments in the National Institutes of Health (NIH) and the National Cancer Institute (NCI), is...

lung cancer

Study Examines Combined Impact of Aspirin, Metformin, and Statins on Lung Cancer Risk

Combined use of aspirin, metformin, and statins may be associated with decreased lung cancer incidence and mortality, according to a study published by Kang et al in the Journal of Thoracic Oncology. Study Methods The aim of this study was to investigate the associations of the three agents with...

covid-19

Joint Statement From the AMA, AHA, and ANA on U.S. Coronavirus Death Toll

Today, the American Medical Association (AMA), American Hospital Association (AHA), and American Nurses Association (ANA) released a joint statement on the amount of deaths caused by the coronavirus in the United States. Today we mark a somber milestone as more than 200,000 people in the United...

colorectal cancer

Can Drinking Coffee Daily Improve Survival in Patients With Advanced Colorectal Cancer?

In a large group of patients with metastatic colorectal cancer, consumption of a few cups of coffee a day was associated with longer survival and reduced risk of disease progression, according to findings reported by Mackintosh et al in JAMA Oncology. The findings, based on data from a large...

breast cancer

Impact of Neoadjuvant Endocrine Therapy and Neoadjuvant Chemotherapy on Rates of Breast‑Conserving Surgery

“Studies that have compared neoadjuvant endocrine therapy with neoadjuvant chemotherapy have shown low pathologic complete response rates with both approaches. However, the rates of breast-conserving surgery have been shown to be slightly higher with neoadjuvant endocrine therapy,” Kelly Hunt, MD,...

lung cancer

Study Questions Role of Routine Postoperative Radiotherapy in NSCLC With Mediastinal Nodes

The Lung ART trial was designed to demonstrate whether there was any benefit to the routine use of modern mediastinal postoperative radiotherapy in patients with non–small cell lung cancer (NSCLC) following complete resection and (neo)adjuvant chemotherapy. No difference in disease-free survival...

issues in oncology

ESMO 2020: Access to Treatments and Trials Varies Widely for Patients With Cancer Across Europe

Access to cancer treatments is highly unequal across Europe, both for new drugs in development (due to disparities in access to clinical trials) and for currently approved drugs (due to disparities in health-care spending by different countries), according to results from two studies being...

issues in oncology

Caring for Undocumented Patients With Cancer

There are approximately 25 million foreign-born immigrants living in the United States, which is more than 13% of the nation’s total population. Of these individuals, it is estimated that about 11 million are undocumented; by far, the largest group of this immigrant undocumented population is...

pancreatic cancer

Researchers Report on Comprehensive Analysis of Adenosquamous Carcinoma of the Pancreas

In a comprehensive analysis of adenosquamous cancer of the pancreas in preclinical models, researchers identified potential therapeutic targets for this aggressive form of pancreatic cancer. They also identified already-available agents—designed to treat other types of cancer—that may be useful in...

issues in oncology

Inaugural AACR Cancer Disparities Progress Report Released

The American Association for Cancer Research (AACR) released its inaugural Cancer Disparities Progress Report 2020, which found that while overall cancer death rates are declining and the number of survivors is reaching record highs, progress against cancer is not benefiting everyone equally, with...

Advertisement

Advertisement




Advertisement